John T Lucas1, Matthew M Ladra2, Shannon M MacDonald3, Paul M Busse3, Alison M Friedmann4, David H Ebb4, Karen J Marcus5, Nancy J Tarbell3, Torunn I Yock3. 1. Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina. 2. Provision Center for Proton Therapy, Knoxville, Tennessee. 3. Department of Radiation Oncology, Boston, Massachusetts. 4. Pediatrics at Massachusetts General Hospital, Boston, Massachusetts. 5. Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: Esthesioneuroblastoma (EN) of the paranasal sinus comprises less than 3% of tumors of in pediatric and adolescent patients [1]. The collective adult literature indicates a critical role for radiotherapy in attaining cure [2], yet pediatric outcome data is limited. Radiation in pediatric patients with EN can cause significant morbidity due to the proximity of critical structures. Proton radiotherapy offers a potential dosimetric benefit that may improve long-term survival and toxicity outcomes in the pediatric population [3]. METHODS: We retrospectively identified eight patients treated for EN with proton radiotherapy from 2000-2013. Times to event clinical endpoints are summarized using the Kaplan-Meier methods and are from the date of radiotherapy completion. Toxicities are reviewed and graded according to CTCAE v. 4.0. RESULTS: Median follow up was 4.6 years for survivors (range 0.8-9.4 years). The 4 year overall survival was 87.5%. Four of eight patients (one elective) had comprehensive neck radiotherapy. No local or regional failures were observed. Two patients failed distantly with diffuse leptomeningeal disease and intraparenchymal brain metastases, at 0.6 and 1.3 months respectively. Four patients developed radiation related late toxicities including endocrine dysfunction, two cases of grade 2 retinopathy and one case of grade 3 optic neuropathy. CONCLUSIONS: In a limited cohort, proton radiotherapy appears to provide excellent locoregional disease control even in those patients with locally advanced disease and intracranial extension. Distant failure determined overall survival in our cohort. Toxicities were acceptable given disease location and extent.
BACKGROUND: Esthesioneuroblastoma (EN) of the paranasal sinus comprises less than 3% of tumors of in pediatric and adolescent patients [1]. The collective adult literature indicates a critical role for radiotherapy in attaining cure [2], yet pediatric outcome data is limited. Radiation in pediatric patients with EN can cause significant morbidity due to the proximity of critical structures. Proton radiotherapy offers a potential dosimetric benefit that may improve long-term survival and toxicity outcomes in the pediatric population [3]. METHODS: We retrospectively identified eight patients treated for EN with proton radiotherapy from 2000-2013. Times to event clinical endpoints are summarized using the Kaplan-Meier methods and are from the date of radiotherapy completion. Toxicities are reviewed and graded according to CTCAE v. 4.0. RESULTS: Median follow up was 4.6 years for survivors (range 0.8-9.4 years). The 4 year overall survival was 87.5%. Four of eight patients (one elective) had comprehensive neck radiotherapy. No local or regional failures were observed. Two patients failed distantly with diffuse leptomeningeal disease and intraparenchymal brain metastases, at 0.6 and 1.3 months respectively. Four patients developed radiation related late toxicities including endocrine dysfunction, two cases of grade 2 retinopathy and one case of grade 3 optic neuropathy. CONCLUSIONS: In a limited cohort, proton radiotherapy appears to provide excellent locoregional disease control even in those patients with locally advanced disease and intracranial extension. Distant failure determined overall survival in our cohort. Toxicities were acceptable given disease location and extent.
Authors: Mahmut Ozsahin; Guenther Gruber; Olimpia Olszyk; Omur Karakoyun-Celik; Berrin Pehlivan; David Azria; Martine Roelandts; Johannes H A M Kaanders; Mustafa Cengiz; Marco Krengli; Oscar Matzinger; Abderrahim Zouhair Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-16 Impact factor: 7.038
Authors: Jamie J Van Gompel; Matthew L Carlson; Bruce E Pollock; Eric J Moore; Robert L Foote; Michael J Link Journal: Neurosurgery Date: 2013-03 Impact factor: 4.654
Authors: Gideon Bachar; David P Goldstein; Manish Shah; Asheesh Tandon; Jolie Ringash; Gregory Pond; Patrick J Gullane; Bayardo Perez-Ordonez; Ralph W Gilbert; Dale H Brown; Fred Gentili; Brian O'Sullivan; Jonathan C Irish Journal: Head Neck Date: 2008-12 Impact factor: 3.147
Authors: Satoshi Kiyofuji; Vijay Agarwal; Joshua D Hughes; Robert L Foote; Jeffrey R Janus; Eric J Moore; Caterina Giannini; Michael J Link; Jamie J Van Gompel Journal: J Neurol Surg B Skull Base Date: 2020-03-25